Company News: AstraZeneca

Share this article:
The FDA approved Crestor for use in patients who are not currently suffering from heart disease but who may be considered at-risk based on age (50 and over for men, 60 and over for women), elevated CRP levels and at least one other risk factor, including smoking, hypertension, low HDL-C or family history of early heart disease. In observance of the PhRMA guiding principles on DTC, the brand will defer consumer advertising on the expanded label for awhile while reps detail doctors on it first. Messaging around the brand's unique indication for slowing the progression of atherosclerosis will continue to be a key part of the brand's overall message, said an AstraZeneca spoke.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.